Cargando…

Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition

Inhibition of the canalicular phospholipid floppase multidrug resistance protein 3 (MDR3) has been implicated in cholestatic drug-induced liver injury (DILI), which is clinically characterized by disrupted bile flow and damage to the biliary epithelium. Reduction in phospholipid excretion, as a cons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beaudoin, James J., Yang, Kyunghee, Adiwidjaja, Jeffry, Taneja, Guncha, Watkins, Paul B., Siler, Scott Q., Howell, Brett A., Woodhead, Jeffrey L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887159/ https://www.ncbi.nlm.nih.gov/pubmed/36733378 http://dx.doi.org/10.3389/fphar.2022.1085621

Ejemplares similares

Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
por: Woodhead, Jeffrey L., et al.
Publicado: (2014)

Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI
por: Woodhead, J L, et al.
Publicado: (2014)

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics
por: Yang, Y., et al.
Publicado: (2014)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury
por: Longo, Diane M, et al.
Publicado: (2019)

Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity
por: Yang, Kyunghee, et al.
Publicado: (2014)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018)

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
por: Adiwidjaja, Jeffry, et al.
Publicado: (2020)

Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
por: Reis, Mariana Alves, et al.
Publicado: (2020)

A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial
por: Howell, B A, et al.
Publicado: (2014)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling
por: Woodhead, Jeffrey L., et al.
Publicado: (2019)

Mechanism of Paeoniflorin in the Treatment of Bile Duct Ligation-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology
por: Wei, Shizhang, et al.
Publicado: (2020)

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling
por: Woodhead, Jeffrey L, et al.
Publicado: (2022)

Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses
por: Shoda, Lisl KM, et al.
Publicado: (2017)

Metabolomic Assessment of Acute Cholestatic Injuries Induced by Thioacetamide and by Bile Duct Ligation, and the Protective Effects of Huang-Lian-Jie-Du-Decoction
por: Wei, Dan-Dan, et al.
Publicado: (2018)

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
por: Wang, Gangyang, et al.
Publicado: (2022)

Editorial: Considering plant metabolites and their synthetic derivatives as candidates for the development of drugs against multidrug resistant (MDR) tumors
por: Rijo, Patricia, et al.
Publicado: (2022)

Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
por: Zhang, Fangling, et al.
Publicado: (2022)

The role of bile acids in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2021)

Calcipotriol Inhibits NLRP3 Signal Through YAP1 Activation to Alleviate Cholestatic Liver Injury and Fibrosis
por: Wang, Xiaopeng, et al.
Publicado: (2020)

Bile Nephropathy in Flucloxacillin-Induced Cholestatic Liver Dysfunction
por: Alnasrallah, Basil, et al.
Publicado: (2016)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

Bile acid-mediated signaling in cholestatic liver diseases
por: Zeng, Jing, et al.
Publicado: (2023)

Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity
por: Battista, Christina, et al.
Publicado: (2018)

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors
por: Woodhead, Jeffrey L., et al.
Publicado: (2017)

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury
por: Longo, DM, et al.
Publicado: (2016)

Phytochemicals: Potential Lead Molecules for MDR Reversal
por: Tinoush, Boshra, et al.
Publicado: (2020)

The Combination of a Human Biomimetic Liver Microphysiology System with BIOLOGXsym, a Quantitative Systems Toxicology (QST) Modeling Platform for Macromolecules, Provides Mechanistic Understanding of Tocilizumab- and GGF2-Induced Liver Injury
por: Beaudoin, James J., et al.
Publicado: (2023)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology
por: Chen, Lisheng, et al.
Publicado: (2021)

Integrating Network Analysis and Metabolomics to Reveal Mechanism of Huaganjian Decoction in Treatment of Cholestatic Hepatic Injury
por: Dong, Qin, et al.
Publicado: (2022)

Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
por: Song, Shuailing, et al.
Publicado: (2023)

SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression
por: Xia, Yang Q., et al.
Publicado: (2018)

Pathobiochemical signatures of cholestatic liver disease in bile duct ligated mice
por: Abshagen, Kerstin, et al.
Publicado: (2015)

MRGPRX4 is a bile acid receptor for human cholestatic itch
por: Yu, Huasheng, et al.
Publicado: (2019)

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
por: Shi, Qingmiao, et al.
Publicado: (2023)

PHB2 interacts with LC3 and SQSTM1 is required for bile acids-induced mitophagy in cholestatic liver
por: Xiao, Yongtao, et al.
Publicado: (2018)

Borneol influences the pharmacokinetics of florfenicol through regulation of cytochrome P450 1A2 (CYP1A2), CYP2C11, CYP3A1, and multidrug resistance 1 (MDR1) mRNA expression levels in rats
por: LI, Xuting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qvcndb39n1crae2meihuhdt4e8